Regeneron Pharmaceuticals ((REGN)), Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Regeneron Pharmaceuticals and Sanofi are conducting a clinical study titled A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis. The study aims to evaluate the pharmacokinetics and safety of Dupilumab in young participants suffering from Prurigo Nodularis, a chronic skin condition. This research is significant as it could lead to new treatment options for a demographic that currently has limited therapeutic choices.
The intervention being tested is Dupilumab, an experimental drug administered subcutaneously. It is designed to treat Prurigo Nodularis by targeting specific pathways involved in the inflammatory response, potentially providing relief from symptoms.
This Phase 3 study is interventional with a single-group assignment. It is open-label, meaning there is no masking, and its primary purpose is treatment. Participants will undergo a 42 to 44-week process, including screening, treatment, and follow-up periods.
The study began on May 15, 2024, with an estimated primary completion date yet to be announced. The latest update was submitted on August 19, 2025. These timelines are crucial for investors tracking the progress and potential market entry of Dupilumab for this indication.
The ongoing study could significantly impact the stock performance of Regeneron and Sanofi, as successful results may enhance their market position and investor confidence. The development of Dupilumab for Prurigo Nodularis could also influence the competitive landscape, potentially affecting other companies in the dermatological treatment sector.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.